Kombinationstherapie zur Behandlung von Krebs
Anmelder: Novartis AG 🇨🇭
Details
- Veröffentlichungs-Nr.
- EP4772247
- Anmeldetag
- 7. August 2014
- Veröffentlichung
- 8. Juli 2026
- Rechtsraum
- EP
- IPC
- A61P35/00
Abstract
The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.
Anmelder
- Firma
- Novartis AG
- Land
- 🇨🇭 Schweiz
Schweizer Pharmakonzern mit Sitz in Basel. Aktiv in der Erforschung und Entwicklung von Arzneimitteln, Biotechnologie sowie Diagnostik in Bereichen wie Onkologie, Kardiologie, Immunologie und Neurowissenschaften.
6.171 Patente in unserer Datenbank